Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 4/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | GRM5 | P41594 | 6/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.46 |
| ▸ | CSF1R | P07333 | 2/20 | 0.46 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.46 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.46 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.46 |
| ▸ | PAK4 | O96013 | 1/20 | 0.46 |
| ▸ | RET | P07949 | 1/20 | 0.46 |
| ▸ | GRK5 | P34947 | 1/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.46 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.46 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.46 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.46 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22130331 | 0.82 | DYRK1A (0.70) | DYRK1AKDM4EALDH1A1GLAHPGD | |
| SCHEMBL22130319 | 0.82 | DYRK1A (0.70) | DYRK1AKDM4EALDH1A1GLAHPGD | |
| SCHEMBL1829687 | 0.82 | DYRK1A (0.59) | DYRK1AGRM5 | |
| SCHEMBL24155657 | 0.81 | DYRK1A (0.55) | DYRK1AKDM4EALDH1A1GLAHPGD | |
| SCHEMBL12403385 | 0.78 | DYRK1A (0.64) | DYRK1AKDM4EALDH1A1GLAHPGD | |
| SCHEMBL30639468 | 0.78 | DYRK1A (0.55) | DYRK1AKDM4EALDH1A1GRM5CLK4 | |
| SCHEMBL30639453 | 0.77 | DYRK1A (0.63) | DYRK1AGRM5DYRK1BRETCLK4 | |
| SCHEMBL2541515 | 0.75 | DYRK1A (0.47) | DYRK1AKDM4EALDH1A1GLAHPGD | |
| SCHEMBL30639477 | 0.75 | DYRK1A (0.64) | DYRK1AGRM5 | |
| SCHEMBL21436086 | 0.75 | DYRK1A (0.59) | DYRK1AKDM4EALDH1A1GLAGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2396330-B1 | FUSED PYRIMIDINES | BAYER IP GMBH (DE) | 2016-04-06 | — | — | EP | disclosed |
| US-8957064-B2 | Fused pyrimidines | BAYER INTELLECTUAL PROPERTY GMBH (US) | 2015-02-17 | — | — | US | disclosed |
| US-8614218-B2 | Fused bicyclic pyrimidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-12-24 | — | — | US | disclosed |
| US-20130317002-A1 | FUSED PYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-11-28 | — | — | US | disclosed |
| US-20130184273-A1 | BICYCLIC PYRIMIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-18 | — | — | US | disclosed |
| EP-2593458-A1 | BICYCLIC PYRIMIDINES | Bayer Intellectual Property GmbH (DE) | 2013-05-22 | — | — | EP | disclosed |
| EP-2188291-B1 | FUSED BICYCLIC PYRIMIDINES | Bayer Pharma AG (DE) | 2012-09-19 | — | — | EP | disclosed |
| WO-2012007416-A1 | BICYCLIC PYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-19 | — | — | WO | disclosed |
| EP-2396330-A1 | FUSED PYRIMIDINES | Bayer Pharma Aktiengesellschaft (DE) | 2011-12-21 | — | — | EP | disclosed |
| WO-2010091808-A1 | FUSED PYRIMIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-08-19 | — | — | WO | disclosed |
| US-20090156617-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2009-06-18 | — | — | US | disclosed |
| US-20090156617-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2009-06-18 | — | — | US | disclosed |
| US-20090137607-A1 | FUSED BICYCLIC PYRIMIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-05-28 | — | — | US | disclosed |
| EP-2050748-A1 | Novel fused pyrimidines | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-04-22 | — | — | EP | disclosed |
| EP-1881986-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2008-01-30 | — | — | EP | disclosed |
| EP-1431299-B1 | IMIDAZO(1,2-a)PYRIMIDINES AND FUNGICIDE COMPOSITIONS CONTAINING THE SAME | SUMITOMO CHEMICAL CO (JP) | 2007-05-23 | — | — | EP | disclosed |
| US-7211545-B2 | Imidazo[1,2-a]pyrimidine and fungicidal compositions containing thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-05-01 | — | — | US | disclosed |
| WO-2006124354-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2006-11-23 | — | — | WO | disclosed |
| US-20040235865-A1 | Imidazo[1,2-a]pyrimidine and fungicidal compositions containing thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-11-25 | — | — | US | disclosed |
| EP-1431299-A1 | IMIDAZO(1,2-a)PYRIMIDINES AND FUNGICIDE COMPOSITIONS CONTAINING THE SAME | Sumitomo Chemical Company, Limited (JP) | 2004-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184273-A1 | BICYCLIC PYRIMIDINES | PIK3CA, TYMS, PIK3CD | DYRK1A 3306/4885KDM4E 2817/4885ALDH1A1 1872/4885 |
| US-20040235865-A1 | Imidazo[1,2-a]pyrimidine and fungicidal compositions containing thereof | CBR1, NAT1, CBR3 | DYRK1A 4235/4885KDM4E 3821/4885ALDH1A1 226/4885 |
| US-20090137607-A1 | FUSED BICYCLIC PYRIMIDINES | PIK3CA, TYMS, MTOR | DYRK1A 949/4885KDM4E 3173/4885ALDH1A1 3182/4885 |
| US-20130317002-A1 | FUSED PYRIMIDINES | PIK3CA, MTOR, TYMS | DYRK1A 1714/4885KDM4E 3716/4885ALDH1A1 3442/4885 |
| US-20090156617-A1 | Tyrosine kinase inhibitors | ABL1, ERBB2, MET | DYRK1A 248/4885KDM4E 958/4885ALDH1A1 1458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.